|
Evaluation of the OncoMasTR prognostic signature in postmenopausal women with primary ER-positive breast cancer. |
|
|
Honoraria - Myriad Genetics; NanoString Technologies |
Consulting or Advisory Role - Myriad Genetics |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Atossa Genetics; Cancer Prevention Pharmaceuticals; Merck; Mycology; Qiagen; Roche |
Speakers' Bureau - Becton Dickinson; Gen-Probe; Hologic |
Research Funding - AstraZeneca (Inst); Aventis Pharma (Inst); Becton Dickinson (Inst); Genera Biosystems (Inst); Myriad Genetics (Inst); Qiagen (Inst) |
Patents, Royalties, Other Intellectual Property - Royalties from Myriad Geneticsto institution of which I receive a share for development of Cell cycle progression score (Prolaris) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - OncoMark |
Consulting or Advisory Role - Carrick Therapeutics |
Research Funding - Carrick Therapeutics |
Patents, Royalties, Other Intellectual Property - Two patents which have been licenced to OncoMark Limited |
Travel, Accommodations, Expenses - OncoMark |
|
|
Honoraria - Myriad Genetics; Novartis; Pfizer |
Consulting or Advisory Role - Genoptix; GTx; Janssen Oncology; Radius Health; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Roche (Inst) |
Other Relationship - Institute of Cancer Research |